14 results
10-K
2014 FY
BLPH
Bellerophon Therapeutics, Inc.
31 Mar 15
Annual report
12:00am
clearances or approvals are unnecessary, the manufacturer may be required to cease marketing or distribution of the products or to recall the modified … enforcement action.
Additionally, the FDA has the authority to require the recall of commercialized products in the event of material deficiencies or defects
S-1
BLPH
Bellerophon Therapeutics, Inc.
13 Jan 15
IPO registration
12:00am
their approval of the product or seize the product;
we may be required to recall the product or change the way the product is administered;
additional … also have to recall our products, if any, which would be time consuming and expensive. Also, negative perceptions in the healthcare and patient
DRS/A
BLPH
Bellerophon Therapeutics, Inc.
21 Nov 14
Draft registration statement (amended)
12:00am
the product;
we may be required to recall the product or change the way the product is administered;
additional restrictions may be imposed … not fail, which could lead to property damage, personal injury or death, and may subject us to lawsuits. We may also have to recall our products
424B4
9b1er
13 Feb 15
Prospectus supplement with pricing info
12:00am
8-K
EX-10.1
a89g5j50w4kd
30 Mar 20
Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market
4:09pm
8-K
EX-1.1
u4qxv564gz4 bhpq73
23 Jan 19
Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
5:05pm
- Prev
- 1
- Next